A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
Clinical trial NCT07743164 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07743164
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-17
- Primary completion
- 2031-08-31
- Enrollment
- 646
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.